Autonomix Medical, Inc. (AMIX)
Healthcare · Medical - Devices · NASDAQ · US
$3.13-8.21%Close
SELLCRISIS · day 42
$3.13-8.21%
Key stats
Short interest · FINRA settlement 2026-09-15
- Market cap
- $2M
- Beta
- -1.30
- P/E (TTM)
- -0.07
- Short % float
- 11.67%
- Days to cover
- 1.0
- SI change
- +4.8%
- 1W
- -20.15%
- 1M
- -31.51%
- vs SPY 1W
- -21.71%
- vs SPY 1M
- -33.27%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Autonomix Reports Positive FDA Feedback Supporting 510(k) Pathway to U.S. Clearance
Autonomix Medical Expands Global Intellectual Property Footprint with European Patent Supporting Precision Neuromodulation Platform
Autonomix Medical Appoints Former Medtronic Chief Regulatory Counsel Sandra Cohen Kalter to Board of Directors
Autonomix Medical Announces Acceptance of Two Abstracts for Poster Presentation at CIRSE 2026
Autonomix Medical Expands Intellectual Property Portfolio with New U.S. Patent Covering Feedback-Guided Precision Neuromodulation and Targeted Therapy Delivery
Autonomix Medical Enters into $4.9 Million Warrant Inducement Priced at a Premium to Market Under Nasdaq Rules
Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission
Autonomix Medical Congratulates Co-Founder & Chief Medical Officer Dr. Robert Schwartz on Receiving Prestigious 2026 Cardiovascular Tech Forum Lifetime Achievement Award
Autonomix Stock Skyrockets After Obtaining Key Cancer Tech Patent
Autonomix Medical Expands Precision Neuromodulation Platform with Broad New U.S. Patent Supporting Nerve Sensing, Mapping and Targeted Therapy
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Autonomix Medical Demonstrates Renal Nerve Sensing and Neural Activity Change in Preclinical Study
Autonomix Medical Secures New U.S. Patent Strengthening Next-Generation Precision Neuromodulation Platform
Autonomix Medical Granted U.S. Patent for Overactive Bladder Diagnosis and Treatment Platform
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
Autonomix Medical wins new patent for neural sensing technology
Autonomix Medical wins new patent for neural sensing technology
Autonomix Medical Strengthens Global Intellectual Property Position with New Neural Sensing Patent Grant
